• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Terns Pharmaceuticals Inc.

    3/20/25 4:36:40 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email
    S-8 1 tern-s8-q125.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

    Terns Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

    Delaware

     

    98-1448275

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

     

    1065 East Hillsdale Blvd., Suite 100
    Foster City, California

     

     

    94404

    (Address of Principal Executive Offices)

     

    (Zip Code)

    2021 Incentive Award Plan

    2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Amy Burroughs, M.B.A.

    Chief Executive Officer

    Terns Pharmaceuticals, Inc.

    1065 East Hillsdale Blvd., Suite 100

    Foster City, California 94404

    (650) 525-5535

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

     

    Brian A. Johnson

    Wilmer Cutler Pickering Hale and Dorr LLP

    7 World Trade Center

    250 Greenwich Street

    New York, New York 10007

    Telephone: (212) 230-8800

     

    Copies to:

     

    Elona Kogan, Esq.

    Chief Legal Officer

    Terns Pharmaceuticals, Inc.

    1065 East Hillsdale Blvd., Suite 100

    Foster City, California 94404

    (650) 525-5535

     

     

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    Proposed sale to take place as soon after the effective date of the
    registration statement as awards under the plans are exercised and/or vest.

     

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 5,227,594 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Forms S-8 (File No. 333-253085, 333-263340 and 333-271944) are effective: (i) the 2021 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 4,356,329 shares of common stock, and (ii) the 2021 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 871,265 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON
    FORM S-8

    Pursuant to Instruction E of Form S-8, the contents of (i) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on February 12, 2021 (File No. 333-253085), (ii) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 7, 2022 (File No. 333-263340), (iii) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 15, 2023 (File No. 333-271944) and (iv) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 14, 2024 (File No. 333-277943) are incorporated by reference herein.

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

    Item 8. Exhibits

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit Number

     

    Exhibit Description

     

    Form

     

    Date

     

    Number

     

    Filed Herewith

    4.1

     

    Amended and Restated Certificate of Incorporation.

     

    8-K

     

    2/9/2021

     

    3.1

     

     

    4.2

     

    Amended and Restated Bylaws.

     

    8-K

     

    10/10/2023

     

    3.1

     

     

    4.3

     

    Form of Common Stock Certificate.

     

    S-1/A

     

    2/1/2021

     

    4.2

     

     

    5.1

     

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

    X

    99.1(a)#

     

    2021 Incentive Award Plan.

     

    S-8

     

    2/12/2021

     

    99.2(a)

     

     

    99.1(b)#

     

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(b)

     

     

    99.1(c)#

     

    Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(c)

     

     

    99.1(d)#

     

    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(d)

     

     

    99.2#

     

    2021 Employee Stock Purchase Plan.

     

    S-8

     

    2/12/2021

     

    99.3

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

    X

     

    # Indicates management contract or compensatory plan.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on this 20th day of March, 2025.

     

    Terns Pharmaceuticals, Inc.

    By:

    /s/ Amy Burroughs

    Amy Burroughs, M.B.A.

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Amy Burroughs and Andrew Gengos, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

    Signature

    Title

    Date

    /s/ Amy Burroughs

    Chief Executive Officer and Director

    (Principal Executive Officer)

    March 20, 2025

    Amy Burroughs, M.B.A.

     

    /s/ Andrew Gengos

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    March 20, 2025

    Andrew Gengos, M.B.A.

    /s/ David Fellows

    Chairman of the Board of Directors

    March 20, 2025

    David Fellows

    /s/ Robert Azelby

    Director

    March 20, 2025

    Robert Azelby

    /s/ Jeffrey Kindler

    Director

    March 20, 2025

    Jeffrey Kindler, Esq.

    /s/ Hongbo Lu

    Director

    March 20, 2025

    Hongbo Lu, Ph.D.

    /s/ Jill Quigley

    Director

    March 20, 2025

    Jill Quigley, Esq.

    /s/ Radhika Tripuraneni

    Director

    March 20, 2025

    Radhika Tripuraneni, M.D.

    /s/ Heather Turner

    Director

    March 20, 2025

    Heather Turner, J.D.

     

     

     


    Get the next $TERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    2/9/2026$58.00Outperform
    Leerink Partners
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    11/3/2025Mkt Perform → Outperform
    William Blair
    10/15/2025$20.00Buy
    Truist
    9/17/2025$15.00Overweight
    Barclays
    9/4/2025Neutral
    H.C. Wainwright
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    More analyst ratings

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 113,500 shares, in the aggregate, of Terns common stock to the new employees

    2/2/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

    CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announ

    1/7/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

    FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 312,000 shares, in the aggregate, of Terns common stock to the new employees.

    1/2/26 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Turner Heather D

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:07:42 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tripuraneni Radhika

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:07:17 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Azelby Robert

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    2/2/26 6:06:50 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    SEC Filings

    View All

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    1/22/26 4:07:43 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    1/9/26 4:05:23 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:45:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by William Blair

    William Blair upgraded Terns Pharmaceuticals from Mkt Perform to Outperform

    11/3/25 10:27:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Burroughs Amy L. bought $90,230 worth of shares (23,314 units at $3.87), increasing direct ownership by 98% to 47,083 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/25/25 6:08:58 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $57,082 worth of shares (15,000 units at $3.81) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/16/25 6:05:21 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    View All

    Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

    FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

    2/24/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

    FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

    2/20/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

    FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

    11/18/24 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Financials

    Live finance-specific insights

    View All

    Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

    64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a

    12/8/25 2:45:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1

    11/10/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

    Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema

    11/3/25 9:05:00 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care